BAYRY - Drugmakers face clinical trial disruptions amid Russia - Ukraine conflict

The war between Russia and Ukraine has placed U.S. pharma giants conducting clinical trials in the two countries in a tight spot. Despite the American leadership in clinical studies, the contributions made by Russia and Ukraine to R&D efforts are not insignificant. The number of registered clinical trials in the U.S. exceeded 10,000 in 2021, while Ukraine and Russia accounted for more than 1,200 studies in total, Barron’s reported this week citing data from FactSet and The World Health Organization (WHO). Amid the ongoing war and Western sanctions imposed against Russia, some disruptions to clinical studies are expected. The drugmakers, Merck (NYSE:MRK), Pfizer (NYSE:PFE), as well as Bristol Myers Squibb (NYSE:BMY), have all paused the recruitments in their clinical studies in Russia. “So, the reality is the countries have great scientific prowess and have been a center for Merck and indeed other companies,” Merck (MRK) Chief Financial Officer Caroline Litchfield said. Even

For further details see:

Drugmakers face clinical trial disruptions amid Russia - Ukraine conflict